Rates of syphilis have been steadily rising in recent years with an alarming spike in the number of cases of congenital syphilis. These infections are passed from to infants during pregnancy or childbirth and can lead to miscarriage, stillbirth, prematurity, low birthweight, or death shortly after birth. Treatment during pregnancy can help both parent and child, but there is a shortage of Bicillin-L-A, the only antibiotic approved for this population.
Syphilis is a bacterial infection that is passed through skin-to-skin contact with infected lesions. If left untreated, syphilis progresses through four stages. While it remains curable with antibiotics, complications that may develop in the later stages cannot be reversed with treatment and may include serious damage to the brain, heart, nervous system. In some cases syphilis can lead to death.
Bicillin L-A, also called penicillin G benzathine, is the preferred treatment for primary and secondary (P&S) syphilis in adults, infants, and children. It is the only approved treatment for syphilis in pregnant patients. Pfizer—currently the only manufacturer of Bicillin L-A—announced a manufacturing delay in June and suggested that it would likely lead to shortages of the drug through 2024.
The National Coalition of STD Directors (NCSD) surveyed more than 100 sexual health clinics in late August. It found that in the three months prior to the survey, 40% of clinics had attempted to order Bicillin L-A only to be told it was not available. In addition, 28% of clinics said they had to get the drug from a nearby clinic or refer the patients elsewhere for treatment.
This is not the first shortage of this important antibiotic in recent years. Shortages that began in 2005 continued for almost five years. Shortages began again in 2017 as cases of congenital syphilis were beginning to surge. Pfizer says the shortage is a result of the increase in demand, but advocacy organizations aren’t satisfied with that explanation. A letter to the White House Drug Shortage Task Force signed by 39 organizations notes:
We are also highly skeptical of the company’s attempts to primarily blame the shortage on increasing demand, which appears to unfairly deflect blame to communities affected by syphilis. However, trends in syphilis rates are clear and demand has been and will continue to increase for the foreseeable future; if Pfizer was truly caught completely off guard, it raises significant questions about the competency of the company to forecast obvious infectious disease trends.
As the advocates point out, syphilis rates in the United States have been rising steadily since 2000 and increased 32% between 2020 and 2021 alone. Rates have increased among both males and females, in all age groups and regions of the United States. Gay and bisexual men made up almost half (46.5%) of all P&S cases among men in 2021.
The rise in congenital syphilis is particularly alarming as it represents both a failure of STI prevention/treatment and a failure to provide adequate prenatal care. In 2021, there were 77.9 cases per 100,000 live births in the United Sates. This represents a 30.5% increase from 2020 and 219.3% increase from 2017. There were 220 congenital syphilis-related stillbirths and infant deaths in 2021.
The advocacy groups are asking the White House Drug Shortage Task Force to make this issue a priority and work with the manufacturer to ensure adequate supply quickly. In the meantime, the CDC is suggesting that clinicians prioritize Bicillin L-A for pregnant people with syphilis and babies with congenital syphilis and use doxycycline for other populations. The agency is also reminding clinicians of the importance of thorough exams as a way to properly stage syphilis infections because patients with earlier stages of the infection need less Bicillin L-A.
About 1.6 million cases of chlamydia and 600,000 cases of gonorrhea are diagnosed in the United Sates each year. A new study suggests that these patients may not be following through with STI treatment or getting the right antibiotics.
A clinical trial of a new antibiotic found that it works just as well as a current drug regimen for treating gonorrhea infections. This is important because the bacteria that causes gonorrhea has become resistant to most existing antibiotics.
You have probably heard that HPV can cause cervical cancer. But did you know that it can also cause cancers of the mouth, tongue, and throat?
The FDA just approved a new, fully at-home test for chlamydia, gonorrhea, and trichomoniasis. The tests, which is only for women, will be available without a prescription. Users can collect their own sample and have results in less than 30 minutes.
Our reproductive health is an important part of our sexual health and our overall health. It includes our reproductive organs and our ability to get pregnant or get someone pregnant when we choose.
Anyone who is having penis-in-vagina sex runs the risk of getting pregnant every time they have sex. Even if it’s your first time. Even if you have your period. Even if it’s a full moon and Mercury is in retrograde.
ASHA believes that all people have the right to the information and services that will help them to have optimum sexual health. We envision a time when stigma is no longer associated with sexual health and our nation is united in its belief that sexuality is a normal, healthy, and positive aspect of human life.
ABOUT
GET INVOLVED
ASHA WEBSITES
GET HELP
© 2025 American Sexual Health Association